CARDIOPROTECTIVE EFFECT OF ERYTHROPOIETINS AT PREDIALYSIS STAGES OF CHRONIC RENAL DISEASES
The paper analyzes the data of international and multicenter national studies of the impact of early erythropoietin correction of anemia on cardiovascular morbidity and mortality in patients with chronic renal disease (CRD) Although the cardioprotective effect of renal anemia correction has been proven, the problem associated with target hemoglobin to be achieved during therapy remains open. It is suggested that the lower levels of hemoglobin and hematocrit are «physiological» in CRD patients with cardiovascular diseases under oxidative stress than in healthy individuals. It should be borne in mind that the antianemic effect of erythropoietin may reduce when co-administered with immunosuppressive or antiviral therapy, as well as with renin-angiotensin blockers. On the other hand, the effect of erythropoietin in combination with angiotensin-converting enzyme inhibitors is higher than therapeutic ones despite incomplete anemia correction. Erythropoietin maintains its cardioprotective effect.